参苓白术散加减联合脐疗治疗腹泻型肠易激综合征的疗效观察
|
摘要
【目的】观察参苓白术散加减联合脐疗治疗腹泻型肠易激综合征(IBS-D)的临床疗效。【方法】将80例IBS-D患者随机分为试验组和对照组,每组各40例。试验组给予参苓白术散加减联合脐疗治疗,对照组给予匹维溴胺片口服治疗,连续治疗6周为1个疗程。观察2组患者治疗前后中医证候评分和肠易激综合征生活质量专用量表(IBS-QOL)评分的变化情况,并评价2组的临床疗效。【结果】(1)治疗6周后,试验组的总有效率为90.0%,对照组为72.5%,试验组的疗效明显优于对照组,差异有统计学意义(P<0.05)。(2)治疗后,2组患者腹痛、大便性状、大便次数、神疲乏力等主要证候评分均较治疗前降低(P <0.05),且试验组的降低作用均明显优于对照组(P <0.05)。(3)治疗后,2组患者的生活质量评分均较治疗前明显提高(P<0.05),且试验组对生活质量评分的提高作用明显优于对照组(P<0.01)。【结论】参苓白术散联合脐疗治疗IBS-D具有较好疗效,能有效缓解胃肠道症状,提高患者生活质量,其疗效优于西药匹维溴胺。
Objective To observe the effect of modified Shenling Baizhu Powder combined with umbilical therapy for the treatment of diarrhea-predominant irritable bowel syndrome(IBS-D). Methods Eighty cases of IBS-D patients were randomly divided into trial group and control group,40 cases in each group. Patients in the trial group were treated by modified Shenling Baizhu Powder orally combined with umbilical therapy of ginger partition moxibustion, and the control group was given oral use of Pinaverium Bromide Tablets. Six continuous weeks constituted one course of the treatment. Before and after treatment, the scores of traditional Chinese medicine syndromes and the scores of the quality of life scale for irritable bowel syndrome(IBS-QOL)were observed. After treatment,the clinical effect of the two groups was evaluated. Results(1)After 6 weeks of continuous treatment,the total effective rate of the trial group was 90.0%,being superior to that(72.5%)of the control group(P < 0.05).(2)After treatment,the scores of the main clinical symptoms such as abdominal pain,stool traits,defecation frequency, and lassitude in the two groups were significantly decreased(P < 0.05 compared with those before treatment),and the decrease in the trial group was superior to that in the control group(P < 0.05).(3)After treatment, the scores of the IBS-QOL were significantly increased(P < 0.05 compared with those before treatment),and the increase in the trial group was superior to that in the control group(P < 0.01). Conclusion Modified Shenling Baizhu Powder combined with umbilical therapy exerts certain effect for the treatment of IBS-D by relieving the gastrointestinal symptoms and improving the QOL,and its effect is stronger than that of western medicine of Pinaverium Bromide Tablets.
Objective To observe the effect of modified Shenling Baizhu Powder combined with umbilical therapy for the treatment of diarrhea-predominant irritable bowel syndrome(IBS-D). Methods Eighty cases of IBS-D patients were randomly divided into trial group and control group,40 cases in each group. Patients in the trial group were treated by modified Shenling Baizhu Powder orally combined with umbilical therapy of ginger partition moxibustion, and the control group was given oral use of Pinaverium Bromide Tablets. Six continuous weeks constituted one course of the treatment. Before and after treatment, the scores of traditional Chinese medicine syndromes and the scores of the quality of life scale for irritable bowel syndrome(IBS-QOL)were observed. After treatment,the clinical effect of the two groups was evaluated. Results(1)After 6 weeks of continuous treatment,the total effective rate of the trial group was 90.0%,being superior to that(72.5%)of the control group(P < 0.05).(2)After treatment,the scores of the main clinical symptoms such as abdominal pain,stool traits,defecation frequency, and lassitude in the two groups were significantly decreased(P < 0.05 compared with those before treatment),and the decrease in the trial group was superior to that in the control group(P < 0.05).(3)After treatment, the scores of the IBS-QOL were significantly increased(P < 0.05 compared with those before treatment),and the increase in the trial group was superior to that in the control group(P < 0.01). Conclusion Modified Shenling Baizhu Powder combined with umbilical therapy exerts certain effect for the treatment of IBS-D by relieving the gastrointestinal symptoms and improving the QOL,and its effect is stronger than that of western medicine of Pinaverium Bromide Tablets.
引文
[1]唐承薇,张澍田.内科学消化内科分册[M].北京:人民卫生出版社,2015:115
[2]中华中医药学会脾胃病分会.肠易激综合征中医诊疗专家共识意见(2017)[J].中医杂志,2017,58(18):1615.
[3]陈明显,蔡淦.肠易激综合征生活质量评价的研究现状及展望[J].世界华人消化杂志,2011,19(1):1.
[4]钱鑫,叶柏.腹泻型肠易激综合征的中西医治疗[J].中国医学工程,2013,21(10):73.
[5]黄绍刚,黎颖婷.中药复方肠激灵治疗腹泻型肠易激综合征随机对照临床研究[J].广州中医药大学学报,2013,30(2):152.
[6] Drossman D A,Hasler W L. RomeⅣ-functional GI disorders:disorders of gut-brain interaction[J]. Gastroenterology, 2016,150(6):1257.
[7]郑筱萸.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:374-376.
[8]于洪波,李爱萍,戴林.肠易激综合征的治疗现状及研究进展[J].胃肠病学和肝病学杂志,2014,23(6):609.
[9]李德锋,徐陆周,周晓虹.腹泻型肠易激综合征病机治则探析[J].辽宁中医药大学学报,2012,14(5):104.
[10]燕麟,周正华.腹泻型肠易激综合征的病机及治法探析[J].陕西中医,2015,36(9):1218.
[11]丁维俊,周邦靖,翟慕东,等.参苓白术散对小鼠脾虚模型肠道菌群的影响[J].北京中医药大学学报,2006,29(8):530.
[12]高秀花.神阙穴古今临床应用探析[J].湖南中医杂志,2015,31(2):81.
[13]凌希,赵彩娇.神阙穴的临床运用概述[J].临床医药文献杂志,2016,3(55):10940.
[2]中华中医药学会脾胃病分会.肠易激综合征中医诊疗专家共识意见(2017)[J].中医杂志,2017,58(18):1615.
[3]陈明显,蔡淦.肠易激综合征生活质量评价的研究现状及展望[J].世界华人消化杂志,2011,19(1):1.
[4]钱鑫,叶柏.腹泻型肠易激综合征的中西医治疗[J].中国医学工程,2013,21(10):73.
[5]黄绍刚,黎颖婷.中药复方肠激灵治疗腹泻型肠易激综合征随机对照临床研究[J].广州中医药大学学报,2013,30(2):152.
[6] Drossman D A,Hasler W L. RomeⅣ-functional GI disorders:disorders of gut-brain interaction[J]. Gastroenterology, 2016,150(6):1257.
[7]郑筱萸.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:374-376.
[8]于洪波,李爱萍,戴林.肠易激综合征的治疗现状及研究进展[J].胃肠病学和肝病学杂志,2014,23(6):609.
[9]李德锋,徐陆周,周晓虹.腹泻型肠易激综合征病机治则探析[J].辽宁中医药大学学报,2012,14(5):104.
[10]燕麟,周正华.腹泻型肠易激综合征的病机及治法探析[J].陕西中医,2015,36(9):1218.
[11]丁维俊,周邦靖,翟慕东,等.参苓白术散对小鼠脾虚模型肠道菌群的影响[J].北京中医药大学学报,2006,29(8):530.
[12]高秀花.神阙穴古今临床应用探析[J].湖南中医杂志,2015,31(2):81.
[13]凌希,赵彩娇.神阙穴的临床运用概述[J].临床医药文献杂志,2016,3(55):10940.